e-learning
resources
London 2016
Monday, 05.09.2016
Effect of sleep apnoea on life-span and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
OSA with intertitial lung diseases
Sema Saraç (Istanbul, Turkey), Sema Saraç, Gulgun Çetintas, Murat Kavas, Özlem Oruç, Özgür Bilgin Topçuoglu, Cüneyt Saltürk, Meral Uluköylü, Cansel Atinkaya, Sibel Arinç, Ali Metin Görgüner
Source:
International Congress 2016 – Effect of sleep apnoea on life-span and comorbidities
Session:
Effect of sleep apnoea on life-span and comorbidities
Session type:
Thematic Poster
Number:
2357
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sema Saraç (Istanbul, Turkey), Sema Saraç, Gulgun Çetintas, Murat Kavas, Özlem Oruç, Özgür Bilgin Topçuoglu, Cüneyt Saltürk, Meral Uluköylü, Cansel Atinkaya, Sibel Arinç, Ali Metin Görgüner. OSA with intertitial lung diseases. Eur Respir J 2016; 48: Suppl. 60, 2357
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Rituximab in severe, treatment-refractory interstitial lung disease
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Study of factors affecting mortality in ILD cases over 2 years
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Rituximab in severe, progressive interstitial lung disease
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Pulmonary involvement in children with rheumatic diseases
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
HCMV infection triggers the development of interstitial lung diseases in autoimmune disorders
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Evaluation of sleep related breathing disorders and obstructive sleep apnea in patients with interstitial lung disease
Source: Annual Congress 2013 –Sleep disordered breathing in special situations II
Year: 2013
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Metabolic syndrome in interstitial lung diseases
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease
Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases
Year: 2016
Clinical analysis of lung manifestation in Sjögren's syndrome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Plethysmographic profil of patients with infiltrative lung diseases
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
The prognostic factor in patients with myositis-associated interstitial lung disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Safety and advantages of VATS biopsy in diagnosis of interstitial lung disease
Source: International Congress 2015 – Challenges in surgery for non-malignant disorders: pleural mediastinal and tracheal problems, congenital disorders
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept